AIC
KROS icon

Ayalon Insurance Company’s Keros Therapeutics KROS Stock Holding History

Ayalon Insurance Company’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,694
Closed -$70K – 154
2021
Q2 		$70K Buy
+1,694
New +$91.8K 0.02% 149

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Ayalon Insurance Company's KROS Position: Q3 2021 in Review

Ayalon Insurance Company sold out of Keros Therapeutics (KROS) in Q3 2021, closing a stake of 1,694 shares — an estimated $70K sold.

Ayalon Insurance Company first reported a position in KROS in Q2 2021 and held it in 1 quarter. The position peaked at $70K in Q2 2021. 88 funds tracked by Wall St. Rank hold KROS as of Q3 2021.

  • Ayalon Insurance Company reported no remaining Keros Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ayalon Insurance Company sold 1,694 Keros Therapeutics shares in Q3 2021, an estimated $70K.
  • Ayalon Insurance Company first reported a position in Keros Therapeutics in Q2 2021 and held it in 1 quarter.
  • Ayalon Insurance Company's Keros Therapeutics position peaked at $70K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2021.

Based on Ayalon Insurance Company's 13F filing for Q3 2021, filed 13 Oct 2021.